icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 23rd Conference of the Asian Pacific
Association for the Study of the Liver
6-9 June
2013, Singapore
Back grey_arrow_rt.gif
 
 
 
Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor[protease]) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV)....and triple all-oral Daclatasvir+Asunaprevir+Rbv (gt1a/1b)
 
 
  Reported by Jules Levin
 
APASL Liver Week 2013: The 2013 Annual Meeting of the
Asian Pacific Association for the Study of the Liver
Singapore, June 6-10, 2013
 
EASL: Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (04/25/13)
 
Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S-P, Wind-Rotolo M, McPhee F, Grasela DM, and Pasquinelli C

APASL1.gif

APASL2.gif

APASL3.gif

APASL4.gif

APASL5.gif

APASL6.gif

APASL7.gif

APASL8.gif

APASL9.gif